Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3956-3965

  Justo, Julie Ann ^a,d   Mayer, Stockton M ^b   Pai, Manjunath P ^c   Soriano, Melinda M ^a   Danziger, Larry H ^a,b   Novak, Richard M ^b   Rodvold, Keith A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTAROLINE M 1; CREATININE; DRUG METABOLITE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; PRODRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; ADOLESCENT; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; COMPUTER SIMULATION; METABOLISM; MIDDLE AGED; MONTE CARLO METHOD; MORBID OBESITY; NORMAL HUMAN; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BODY MASS INDEX; BODY WEIGHT; CEPHALOSPORINS; COMPUTER SIMULATION; CREATININE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; OBESITY; OBESITY, MORBID; PRODRUGS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84931273817     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00498-15     Document Type: Article

References (32)

1. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl 1):S20-S27. http://dx.doi.org/10.1093/cid/cit614.
2. Merker A, Danziger LH, Rodvold KA, Glowacki RC. 2014. Pharmacokinetic and pharmacodynamics evaluation of ceftaroline fosamil. Expert Opin Drug Metab Toxicol 10:1741-1750. http://dx.doi.org/10.1517/17425255.2014.972932.
3. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Rubinstein E, Gin AS, Oban DJ, Karlowsky JA. 2009. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 69:809-831. http://dx.doi.org/10.2165/00003495-200969070-00003.
4. Ogden CL, Carroll MD, Kit BK, Flegal KM. 2014. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311;806-814. http://dx.doi.org/10.1001/jama.2014.732.
5. Bamgbade OA, Rutter TW, Nafiu OO, Dorje P. 2007. Postoperative complications in obese and nonobese patients. World J Surg 31:556-560. http://dx.doi.org/10.1007/s00268-006-0305-0.
6. Bochicchio GV, Buchicchio JM, Nehman S, Tracy JK, Scalea TM. 2006. Impact of obesity in the critically ill trauma patient: a prospective study. J Am Coll Surg 203:533-538. http://dx.doi.org/10.1016/j.jamcollsurg.2006.07.001.
7. Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. 2009. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 10:280-289. http://dx.doi.org/10.1111/j.1467-789X.2008.00546.x.
8. Longo C, Bartlett G, Macgibbon B, Mayo N, Rosenberg E, Nadeau L, Daskalopoulou SS. 2013. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 22:970-976. http://dx.doi.org/10.1002/pds.3461.
9. Wurtz R, Itokazu G, Rodvold K. 1997. Antimicrobial dosing in obese patients. Clin Infect Dis 25:112-118. http://dx.doi.org/10.1086/514505.
10. Pai MP, Bearden DT. 2007. Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 27:1081-1091. http://dx.doi.org/10.1592/phco.27.8.1081.
11. Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE, Vaidyanathan J, Zadenzensky I, Choe S, Sahajwalla CG. 2011. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 90:77-89. http://dx.doi.org/10.1038/clpt.2011.104.
12. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
13. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
14. Akaike H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242. http://dx.doi.org/10.1093/biomet/66.2.237.
15. Bergstrand M, Hook AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
16. Devine BJ. 1974. Gentamicin therapy. Drug Intell Clin Pharm 8:650-655.
17. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. 1983. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643-647. http://dx.doi.org/10.1007/BF00542215.
18. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. 2005. Quantification of lean body weight. Clin Pharmacokinet 44:1051-1065. http://dx.doi.org/10.2165/00003088-200544100-00004.
19. NHLBI Obesity Education Initiative Expert Panel on the Identification Evaluation and Treatment of Obesity in Adults (US). 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heat, Lung, and Blood Institute, Bethesda, MD. http://www.ncbi.nlm.nih.gov/books/NBK2003/.
20. Mosteller RD. 1987. Simplified calculation of body-surface area. N Engl J Med 317:1098.
21. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4.1376-1383.2006.
22. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. 2013. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 57: 2451-2456. http://dx.doi.org/10.1128/AAC.01386-12.
23. Forest Pharmaceuticals, Inc. 2013. Teflaro (ceftaroline fosamil) injection for intravenous use: prescribing information. Forest Pharmaceuticals, Inc., St. Louis, MO.
24. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamics (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55: 601-607. http://dx.doi.org/10.1093/jac/dki079.
25. Riccobene T, Jakate A, Rank D. 2014. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. J Clin Pharmacol 54:742-752. http://dx.doi.org/10.1002/jcph.265.
26. Riccobene TA, Su SF, Rank D. 2013. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Anitmicrob Agents Chemother 57:1496-1504. http://dx.doi.org/10.1128/AAC.02134-12.
27. Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG. 2013. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. J Clin Pharmacol 53:1155-1167. http://dx.doi.org/10.1002/jcph.153.
28. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG. 2013. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 57:6348-6350. http://dx.doi.org/10.1128/AAC.01748-13.
29. Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM. 2014. Pharmacokineticpharmacodynamic target attainment analysis to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 58: 885-891. http://dx.doi.org/10.1128/AAC.01680-13.
30. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG. 2015. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 59:372-380. http://dx.doi.org/10.1128/AAC.02531-14.
31. Ge Y, Liao S, Talbot GH. 2007. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infections (cSSSI). Abstr 47th Intersci Conf Antimicrob Agents Chemother, abstr A-34.
32. Han PY, Kirkpatrick CJ, Green B. 2009. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn 36:147-163. http://dx.doi.org/10.1007/s10928-009-9115-y.